121 results
Page 3 of 7
8-K
EX-99.1
4g4gwdov xs3r
4 Jan 22
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
424B5
20u8nvk9r5a
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
7hcn49xx
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am
8-K
EX-99.1
u5xky541
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
1wg4 lyvaq6
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
0cjlez7
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
xtu94
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
DEFA14A
f28 217y14z87or
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
usz90
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
s4krorei
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
k0fg 1kjpi
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-99.1
l6ygb8ws429
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
EX-99.1
n3pxss3y07e 1y
1 Oct 20
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
4:38pm
8-K
EX-99.2
9zkzm
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm